May 2013
Stanford Medicine;Spring2013, Vol. 30 Issue 1, p15
The article focuses on the Stanford Blood Center blood bank which aims to provide blood and blood products and participate in research on the development of blood disease and blood-borne disease treatments.


Related Articles

  • Umbilical cord blood banks in the UK. Proctor, S J; Dickinson, A M; Parekh, T; Chapman, C // BMJ: British Medical Journal (International Edition);7/14/2001, Vol. 323 Issue 7304, p60 

    Editorial. Discusses umbilical cord blood banks in Great Britain. Use of stem cells from the blood to treat malignant and non-malignant hematological conditions; Survival rates of recipients who received blood from related and unrelated donors; Advantages of cord blood, including no risk to...

  • Cord stem-cell transplantation in Ontario: do we need a public bank? Gassas, A. // Current Oncology;May2011, Vol. 18 Issue 3, pe121 

    It has been 21 years since the first successful use of umbilical cord blood as a source of donor cells for hematopoietic stem cell transplantation (HSCT). Over those years, cord blood transplantation (CBT) has shown marked success as an effective modality in the treatment of children and adults...

  • Insights and Hopes in Umbilical Cord Blood Stem Cell Transplantations. Shahrokhi, Somayeh; Menaa, Farid; Alimoghaddam, Kamran; McGuckin, Colin; Ebtekar, Massoumeh // Journal of Biomedicine & Biotechnology;2012, Vol. 2012, p1 

    Over 20.000 umblical cord blood transplantations (UCBT) have been carried out around the world. Indeed, UCBT represents an attractive source of donor hematopoietic stem cells (HSCs) and, offer interesting features (e.g., lower graft-versus-host disease) compared to bone marrow transplantation...

  • Anemic and considered dangerous. Kaplan, B. // Current Health 2;Nov89, Vol. 16 Issue 3, p10 

    Discusses the different kinds of anemia and how they can be treated. Iron-deficiency anemia; Folic-acid deficiency anemia; B12-deficiency anemia; Sickle-cell anemia; Thalassemia.

  • Hemophilia.  // FDA Consumer;Jun84, Vol. 18 Issue 5, p18 

    Once known as the Royal Disease because it afflicted some European thrones, hemophilia is not just a blue blood's disease, but is a problem for others, including some 20,000 Americans. However, a less expensive and safer treatment may be in the wings for many of its victims.

  • Three products for hemophilia B.  // FDA Consumer;Dec92, Vol. 26 Issue 10, p2 

    Reports that three biological products were licensed by the Food and Drug Administration in August 1992 to prevent or control excessive bleeding from hemophilia B. What hemophilia B is; Bebulin VH, manufactured by Osterreichisches Institut fur Haemoderivate G.m.b.H., Vienna, Austria; Mononine,...

  • New treatment for hemophiliacs.  // FDA Consumer;Mar1993, Vol. 27 Issue 2, p3 

    Reports that the first genetically engineered clotting factor used to treat people with hemophilia A was licensed by the Food and Drug Administration in December 1992. What the product, antihemophilic factor (recombinant), does; What hemophilia A is; Recommendations of FDA's Blood Products...

  • Haemophiliacs' hope.  // New Scientist;2/1/92, Vol. 133 Issue 1806, p19 

    Reports that the British Technology Group and Genetic Therapy of Maryland have signed a worldwide agreement awarding Genetic Therapy the rights to develop gene therapy for treating hemophilia B. Affects 15 percent of hemophiliacs; How doctors treat this presently.

  • A less expensive way to monitor heparin therapy. Cerrato, Paul L. // RN;Jun93, Vol. 56 Issue 6, p19 

    Features low-range activated clotting time (LR-ACT), a bedside test that monitors the effects of heparin therapy, published in the American Journal of Critical Care; Previous method as time-consuming and expensive; Comparison of cost with activated partial thromboplastin time (aPTT).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics